Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

disease awareness

- PMLiVE

Back to mobile basics

Texting as part of a wider healthcare plan

- PMLiVE

Novo Nordisk chooses Mexico to launch urban diabetes plan

‘Cities Changing Diabetes’ partnership programme launches in Mexico City before global roll out

- PMLiVE

MannKind’s inhaled insulin backed for US approval

Afrezza finally on course for FDA approval in diabetes after two rejections

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

Novartis day

Novartis’ German poster campaign to raise vaccination awareness

In-house designed work aims to educate public about meningococcal bacteria

- PMLiVE

Selfie campaign boosts cancer funds

Raises more than £8m for cancer charities

- PMLiVE

Genzyme MS campaign to raise awareness of swimming benefits

Will work with the Multiple Sclerosis Association of America

- PMLiVE

Novo Nordisk will build $100m facility in Denmark

Bagsvaerd site will support growing diabetes pipeline

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

Diabetes awards programme launches

QiC Diabetes 2014 premiered at Diabetes UK conference

- PMLiVE

Lilly/Boehringer’s empagliflozin faces US approval delay

FDA cites manufacturing issues with the new diabetes drug

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links